title: Potassium hydroxide 5% for the treatment of molluscum contagiosum.
abstract: Molluscum contagiosum is a common reason for consultation in primary care. The condition is normally benign and self-limiting1 and the standard advice is to wait for the lesions to resolve spontaneously.2 Recently, potassium hydroxide 5% (MolluDab-Alliance Pharmaceuticals Limited) has been marketed in the UK for the treatment of the condition.3 It is sold as a medical device rather than a licensed medicinal product. Here we consider the evidence for potassium hydroxide 5% in the management of molluscum contagiosum.
mesh_terms: D000279:Administration, Cutaneous; D006801:Humans; D006878:Hydroxides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008976:Molluscum Contagiosum / Q000188:drug therapy*; D017680:Potassium Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D006878:Hydroxides; D017680:Potassium Compounds; C029943:potassium hydroxide